Biofrontera Stock (NASDAQ:BFRI)
Previous Close
$0.86
52W Range
$0.56 - $1.19
50D Avg
$0.99
200D Avg
$0.91
Market Cap
$11.35M
Avg Vol (3M)
$175.32K
Beta
0.85
Div Yield
-
BFRI Company Profile
Biofrontera Inc. is a biopharmaceutical enterprise dedicated to the marketing and distribution of pharmaceutical products within the United States, specifically targeting various dermatological conditions. The company's portfolio includes Ameluz, a prescribed medication designed for photodynamic therapy. This treatment, utilized in conjunction with its licensor's RhodoLED lamp series, addresses mild-to-moderate actinic keratosis on the face and scalp through both localized (lesion-directed) and broader area (field-directed) applications. Furthermore, Biofrontera offers Xepi, a prescription cream indicated for the treatment of impetigo. The firm was founded in 2015 and operates from its headquarters located in Woburn, Massachusetts.
BFRI Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Government and Payor Rebates | $310.00K | $264.00K | $157.00K |
| Co-pay Assistance Program | $165.00K | $675.00K | - |
| Returns | $52.00K | $53.00K | $180.00K |
| Prompt Pay Discounts | $6.00K | $67.00K | $7.00K |
| CoPay Assistance Program | - | - | $374.00K |
Fiscal year ends in Dec 25 | Currency in USD